P. Glennon

发表

Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies

A. Baumbach, R. Stables, N. Curzen, 2010, Circulation.

Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo

Daniel N. Meijles, O. Rackham, A. Clerk, 2021, bioRxiv.

Definition of failed lysis may have influenced outcome in the MERLIN trial.

F. Osman, P. Glennon, Amer Chit, 2005, Journal of the American College of Cardiology.

A simple risk score for prediction of mortality in patients undergoing percutaneous coronary intervention (PCI) for non-ST segment elevation acute coronary syndromes (NSTEACS).

M. Been, F. Osman, S. Constantinides, 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Downregulation of the ERK 1 and 2 mitogen activated protein kinases using antisense oligonucleotides inhibits proliferation of porcine vascular smooth muscle cells.

M. Lewis, E. M. Sale, M. Fisher, 2001, Atherosclerosis.

Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy.

P. Parker, A. Clerk, P. Sugden, 1994, The Journal of biological chemistry.

Regulation of expression of contractile proteins with cardiac hypertrophy and failure

K. Boheler, D. G. Wynne, P. Glennon, 1996, Molecular and Cellular Biochemistry.

Endothelin‐1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes

P. Sugden, M. Bogoyevitch, P. Glennon, 1993, FEBS letters.

Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance.

P. Weissberg, P. Schofield, J. Nordrehaug, 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice

A. Clerk, P. Sugden, S. Fuller, 2022, bioRxiv.

The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension.

Daniel N. Meijles, M. Sheppard, A. Clerk, 2021, Clinical science.

The management of Sjögren's syndrome: British Society for Rheumatology guideline scope.

Coziana Ciurtin, A. Tappuni, S. Rauz, 2020, Rheumatology.

An unusual case of acute on chronic renal failure following percutaneous coronary intervention

P. Glennon, S. Theodorou, 2009, BMJ Case Reports.

Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy.

A. Clerk, P. Sugden, S. Fuller, 1996, The Biochemical journal.

Metastatic melanoma of the gallbladder: A case report and review of the literature

P. Glennon, M. Murphy, S. Lorimer, 1987, Journal of surgical oncology.